JME Group
Oral enzyme replacement therapy (Oral-ERT) and
non-viral gene replacement therapy for human and animal conditions.
"When innovation meets change.... your health starts here !"
Let us show you how JME Group biotech solutions can change your life:
JME Group, Inc. is a privately held, biotechnology company founded on March 2014 in New Jersey, U.S.
The company embarked on a project to develop and commercialize a safer and affordable enzyme replacement therapy (ERT) for metabolic and lysosomal storage diseases (a group of rare (orphan) diseases deficient in lysosomal enzymes) via oral administration (hence Oral-ERT) using plant-derived recombinant human enzymes or proteins plus natural non-GMO plant products for improvement of human and animal health. The first enzyme in the pipeline using this platform is a recombinant human lysosomal acid alpha-glucosidase (GAA) or acid maltase produced in tobacco seeds for the treatment of acid maltase deficiency (AMD or POMPE disease).
Our plan is to clinically develop and commercialize some of these products to initially address the unmet needs of the estimated ~4000 to 5,000 adult and juvenile POMPE patients in the USA and later for the ~120,000 later-onset patients worldwide. However, these estimates will increase by one-third if the fatal infantile cases survive.
We will apply to trademark our oral enzyme replacement therapy as “ Oral-ERT™ & TABZYME ™, POMPEZYME™ "
Added to our innovative products is our Dietary supplement "BARZYME ™ which has promising energy , muscle weakness , and weight maintenance applications. Barzyme will be in production and available through out site first quarter of 2022
Make a donation
Support our cutting-edge research to find better treatments—and ultimately a cure—for Pompe Disease. Your donation fuels hope, innovation, and life-changing breakthroughs for those affected.
Frequency
One time
Monthly
Amount
$100
$250
$500
$1,000
Other
0/100
Comment (optional)